Voyager Therapeutics (VYGR) Share-based Compensation (2014 - 2026)

Voyager Therapeutics has disclosed Share-based Compensation across 13 years of filings, most recently posting $2.5 million for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $2.5 million, down 32.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.6 million (down 8.63% YoY), and the FY2025 annual result was $14.8 million, changed 0.01% from the prior year.
• Share-based Compensation came in at $2.5 million for Q1 2026 at Voyager Therapeutics, down from $3.5 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $4.1 million in Q2 2025 to a low of $2.2 million in Q3 2022.
• The 5-year median for Share-based Compensation is $3.0 million (2023), against an average of $3.1 million.
• Across the five-year window, Share-based Compensation slumped 37.61% in 2022 and jumped 51.27% in 2024, its largest moves.
• Voyager Therapeutics' Share-based Compensation stood at $2.3 million in 2022, then climbed by 29.8% to $3.0 million in 2023, then rose by 22.73% to $3.7 million in 2024, then declined by 5.78% to $3.5 million in 2025, then decreased by 29.34% to $2.5 million in 2026.
• The last three Share-based Compensation figures came in at $2.5 million (Q1 2026), $3.5 million (Q4 2025), and $3.5 million (Q3 2025), per Business Quant data.